Abstract: The present disclosure relates to bifunctional cytokine compositions comprising first and second cytokines connected by a linker, as well as methods of making bifunctional cytokine compositions. The disclosure also relates to bifunctional cytokine compositions comprising interleukins, including interleukin-2, interleukin-7, and interleukin-18, as well as derivatives thereof.

Abstract: A computer-implemented method for improving generalization in training deep neural networks in online settings. The method includes a general learning paradigm for sequential data that is referred to as Learn, Unlearn, RElearn (LURE), a dynamic re-initialization method to address the above-mentioned larger problem of generalization of parameterized networks on sequential data by selectively retaining the task-specific connections through the important criteria and re-randomizing the less important parameters at each mega batch of training. The method of selectively forgetting retains previous information all the while improving generalization to unseen samples.

Abstract: The present disclosure relates to activatable IL-18 polypeptides, compositions comprising activatable IL-18 polypeptides, methods of making the same, and methods of using the activatable IL-18 polypeptides for treatment of diseases. In one aspect, the disclosure relates to the treatment of cancer using the activatable IL-18 polypeptides.

Abstract: The present disclosure relates a modified interleukin 18 (IL-18) polypeptide, methods of making the same, and methods of using the modified IL-18 polypeptides for treatment of diseases including cancer. The modified IL-18 polypeptide can exhibit an ability to induce interferon gamma (IFN?) production when in contact with a cell, exhibit a diminished ability to be inhibited by IL-18 binding protein (IL-18BP) compared to wild type IL-18 (WT IL-18), and exhibit a ratio of half-maximal inhibitory concentration (IC50) by IL-18BP to half-maximal effective concentration (EC50) to induce IFN? production which is greater than that of WT IL-18.

Abstract: The present disclosure relates to modified immunocytokine compositions comprising antibodies or antigen binding fragments specific for immune cell antigens and IL-18 polypeptides. Also provided herein are methods of treatment with and methods of manufacture of immunocytokine compositions.

Abstract: The present disclosure relates to modified IL-2 polypeptides, compositions comprising modified IL-2 polypeptides, methods of making the same, and methods of using the modified IL-2 polypeptides for treatment of diseases including autoimmune diseases. In one aspect, the disclosure relates to the treatment of autoimmune diseases using the modified IL-2 polypeptides. In some embodiments, the disclosed IL-2 polypeptides exhibit enhanced binding to IL-2 receptor ? and/or reduced binding to IL-2 receptor ?. In another aspect, the modified IL-2 polypeptides exhibit enhanced ability to activate T regulatory cells compared to T effector cells.

Abstract: A computer implemented network for executing a self-supervised scene change detection method in which image pairs (T0, T1) from different time instances are subjected to random photometric transformations to obtain two pairs of augmented images (T0 ? T 0?, T 0? ; T1 ? T 1?, T1?), which augmented images are passed into an encoder (f?) and a projection head (g?) to provide corresponding feature representations.

Abstract: The present disclosure relates to modified anti-PD-1 polypeptides, pharmaceutical compositions comprising modified anti-PD-1 polypeptides, methods of making anti-PD-1 polypeptides, and methods of using the modified anti-PD-1 polypeptides for treatment of diseases. In one aspect, the disclosure relates to methods of treating cancer in a subject using the modified anti-PD-1 polypeptides.

Abstract: The present disclosure relates to conjugate compositions comprising an antibody or an antigen binding fragment, a synthetic protein, and a linker. The disclosure further relates to methods of making the conjugate compositions and to methods of using the conjugate compositions for the treatment of diseases. In one aspect, the disclosure relates to the treatment of cancer using the conjugate compositions.

Abstract: The present disclosure relates to modified anti-CD20 polypeptides, compositions comprising modified anti-CD20 polypeptides, methods of making the same, and methods of using the modified anti-CD20 polypeptides for treatment of diseases. In one aspect, the disclosure relates to the treatment of cancer using the modified anti-CD20 polypeptides.

Abstract: The present disclosure relates to modified anti-PD-L1 polypeptides, compositions comprising modified anti-PD-L1 polypeptides, methods of making the same, and methods of using the modified anti-PD-L1 polypeptides for treatment of diseases. In one aspect, the disclosure relates to the treatment of cancer using the modified anti-PD-L1 polypeptides.

Abstract: The present disclosure relates to modified anti-TNF? polypeptides, compositions comprising modified anti-TNF? polypeptides, methods of making the same, and methods of using the modified anti-TNF? polypeptides for treatment of diseases. In one aspect, the disclosure relates to the treatment of inflammatory disorders using the modified anti-TNF? polypeptides.

Abstract: A system and method for providing one or more recommendations. The method encompasses identifying, target feature(s) from a set of features influencing a customer feedback data associated with customer(s) of a digital platform. The method thereafter comprises fine-tuning, a sub-system based on the target feature(s). Further the method encompasses determining, a probability of a promoter rating for the customer(s) based on the fine-tuned sub-system and the customer feedback data. The method thereafter encompasses determining, a contribution of each target feature in the probability of the promoter rating. The method further comprises generating, at least one of a customer insight and a governance parameter, based on the contribution of each target feature in the probability of the promoter rating. Further the method encompasses providing, the one or more recommendations on the digital platform based on at least one of the customer insight and the governance parameter.

Abstract: The present disclosure relates to modified IL-2 polypeptides, compositions comprising modified IL-2 polypeptides, methods of making the same, and methods of using the modified IL-2 polypeptides for treatment of diseases. In one aspect, the disclosure relates to the treatment of cancer using the modified IL-2 polypeptides. In some embodiments, the disclosed IL-2 polypeptides exhibit preferential binding characteristics to IL-2 receptor ?? complex (IL-2R?) over IL-2 receptor ??? complex (IL-2R?). In some embodiments, the molecular weight distribution of the modified IL-2 polypeptides is monodispersed.

Abstract: A computer implemented network for executing a self-supervised scene change detection method, wherein at least one image pair with images captured at different instances of time is processed to detect structural changes caused by an appearance or disappearance of an object in the image pair, and wherein a self-supervised pretraining method is employed that utilizes an unlabelled image pair or pairs to learn representations for scene change detection, and wherein the aligned image pair is subjected to a differencing based self-supervised pre-training method to maximize a correlation between changed regions in the images which provide the structural changes that occur in the image pairs.

Abstract: A system and method for determining market share of an organization. The method encompasses receiving, at least one of a voice of customer data, an internal data of the organization and an external data. The method thereafter leads to determining, one or more set of target features based on at least one of the voice of customer data, the internal data of the organization and the external data. Further the method comprises generating, one or more pre-trained dataset based at least on the one or more set of target features. The method thereafter encompasses receiving, at least one of a first set of feature constraints and a second set of feature constraints. Further the method comprises determining, the market share of the organization based at least on the one or more pre-trained dataset, the first set of feature constraints and the second set of feature constraints.

Abstract: A system and method for generation of a user feedback data is provided. The method encompasses extracting in real time, from social media platform(s), a set of social media posts, wherein each social media post comprises mention(s) related to e-commerce platform(s). The method thereafter encompasses categorizing, each social media post into one of a promotional post and non-promotional post. The method further comprises identifying, a sentiment associated with each social media post. Further, the method encompasses assigning, a customer experience node and/or a business unit with the social media post(s). The method thereafter leads to removing, irrelevant posts from the set of social media posts. The method then generates the user feedback data based on the removal of the at least one irrelevant post and the assigned customer experience node, the assigned business unit and/or the sentiment of each social media post.

Abstract: The present disclosure relates to modified IL-18 polypeptides, compositions comprising modified IL-18 polypeptides, methods of making the same, and methods of using the modified IL-18 polypeptides for treatment of diseases. In one aspect, the disclosure relates to the treatment of cancer using the modified IL-18 polypeptides. In some embodiments, the disclosed IL-18 polypeptides induce the production of IFN?. In some embodiments, the disclosed IL-18 polypeptides induce the production of IFN? without being neutralized by IL-18 binding protein.

Abstract: The present disclosure relates to modified IL-2 polypeptides, compositions comprising modified IL-2 polypeptides, methods of making the same, and methods of using the modified IL-2 polypeptides for treatment of diseases. In one aspect, the disclosure relates to the treatment of cancer using the modified IL-2 polypeptides. In some embodiments, the disclosed IL-2 polypeptides exhibit preferential binding characteristics to IL-2 receptor ?? complex (IL-2R?) over IL-2 receptor ??? complex (IL-2R?). In some embodiments, the molecular weight distribution of the modified IL-2 polypeptides is monodispersed.

Abstract: Systems and methods generate code from a source program where the generated code may be compiled and executed on a Graphics Processing Unit (GPU). A parallel loop analysis check may be performed on regions of the source program identified for parallelization. One or more optimizations also may be applied to the source program that convert mathematical operations into a parallel form. The source program may be partitioned into segments for execution on a host and a device. Kernels may be created for the segments to be executed on the device. The size of the kernels may be determined, and memory transfers between the host and device may be optimized.